Loading...

TLSI TRISALUS LIFE SCIENCES INC Business Restructuring 8-K Filing

TRSL

TLS

TRISALUS LIFE SCIENCES INC

(TLSI)

2025 8-K

Financial Update

Director Resignation

Compensation Increase

Changes in capital structure

Equity Offerings

Financial Statements

Equity Offerings

Director Resignation

Financial Results

Management Change

Credit Facility Agreement

Credit Agreement Drawdown

Board Appointments

Financial Results

Leadership Changes

Financial Results

Management Changes

Financial Update

Entry into Material Definit...

Earnings Report

Credit Agreement

Dismissal of Independent Re...

Earnings Reports

Financial Update

Grant of Stock Option

Financial Update

Financial Results Announcement

Equity Purchase Agreement

Merger of Equals

Special Meeting Approval

Submission of Matters to a ...

Supplemental Disclosures

Rights Offerings

Equity Issuance

Promissory Note Issued

Merger Agreement with TriSa...

Merger Agreement and Subscr...

Merger Agreement

Merger Agreement

Merger Agreement

Merger Agreement and Amendm...

Merger Agreement with TriSa...

Merger Agreement

External Links:

On July 24, 2025, TriSalus Life Sciences, Inc. reported that 98.82% of its outstanding Series A Preferred Stock was tendered for exchange in a recent offer, allowing for amendments to the Preferred Stock terms, effective August 1, 2025.

AI Assistant

TRISALUS LIFE SCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.